BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Søreide K, Gudlaugsson E, Skaland I, Janssen EA, Van Diermen B, Körner H, Baak JP. Metachronous cancer development in patients with sporadic colorectal adenomas-multivariate risk model with independent and combined value of hTERT and survivin. Int J Colorectal Dis 2008;23:389-400. [PMID: 18189140 DOI: 10.1007/s00384-007-0424-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Søreide K. Bacterial genotoxins, gene methylation, and RNA interference: Pointing to colorectal cancer as an infectious disease? Scandinavian Journal of Gastroenterology 2009;43:1529-33. [DOI: 10.1080/00365520802272134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Coghlin C, Murray GI. Biomarkers of colorectal cancer: Recent advances and future challenges. Prot Clin Appl 2015;9:64-71. [DOI: 10.1002/prca.201400082] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
3 Chu DZ, Hussey MA, Alberts DS, Meyskens FL, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Blanke CD, Goodman GE. Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. Clin Colorectal Cancer. 2011;10:310-316. [PMID: 21782524 DOI: 10.1016/j.clcc.2011.06.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
4 Watson MM, Søreide K. The Gut Microbiota Influence on Human Epigenetics, Health, and Disease. Handbook of Epigenetics. Elsevier; 2017. pp. 495-510. [DOI: 10.1016/b978-0-12-805388-1.00032-8] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Miura K, Fujibuchi W, Ishida K, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, Shibata C. Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg Today. 2011;41:175-182. [PMID: 21264751 DOI: 10.1007/s00595-010-4390-1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 4.9] [Reference Citation Analysis]
6 Søreide K, Nedrebø BS, Reite A, Thorsen K, Kørner H. Endoscopy, morphology, morphometry and molecular markers: predicting cancer risk in colorectal adenoma. Expert Rev Mol Diagn 2009;9:125-37. [PMID: 19298137 DOI: 10.1586/14737159.9.2.125] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kohoutova D, Pejchal J, Bures J. Mitotic and apoptotic activity in colorectal neoplasia. BMC Gastroenterol 2018;18:65. [PMID: 29776402 DOI: 10.1186/s12876-018-0786-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Nusko G, Hahn EG, Mansmann U. Characteristics of metachronous colorectal adenomas found during long-term follow-up: analysis of four subsequent generations of adenoma recurrence. Scand J Gastroenterol 2009;44:736-44. [PMID: 19277927 DOI: 10.1080/00365520902770078] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
9 Pellatt AJ, Wolff RK, Herrick J, Lundgreen A, Slattery ML. TERT's role in colorectal carcinogenesis. Mol Carcinog 2013;52:507-13. [DOI: 10.1002/mc.21885] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
10 Søreide K, Nedrebø BS, Knapp J, Glomsaker TB, Søreide JA, Kørner H. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: Potential implications for the surgical oncologist. Surgical Oncology 2009;18:31-50. [DOI: 10.1016/j.suronc.2008.06.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
11 Kanwar JR, Kamalapuram SK, Kanwar RK. Survivin Signaling in Clinical Oncology: A Multifaceted Dragon: SURVIVIN SIGNALING IN CLINICAL ONCOLOGY. Med Res Rev 2013;33:765-89. [DOI: 10.1002/med.21264] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
12 Gupta S, Sun H, Yi S, Storm J, Xiao G, Balasubramanian BA, Zhang S, Ashfaq R, Rockey DC. Molecular markers of carcinogenesis for risk stratification of individuals with colorectal polyps: a case-control study. Cancer Prev Res (Phila) 2014;7:1023-34. [PMID: 25092825 DOI: 10.1158/1940-6207.CAPR-14-0140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
13 Yaku H, Murashima T, Miyoshi D, Sugimoto N. A highly sensitive telomerase activity assay that eliminates false-negative results caused by PCR inhibitors. Molecules 2013;18:11751-67. [PMID: 24071983 DOI: 10.3390/molecules181011751] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
14 Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011;10:188-193. [PMID: 21855041 DOI: 10.1016/j.clcc.2011.03.014] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 5.4] [Reference Citation Analysis]
15 Søreide K, Kørner H, Søreide JA. Diagnostic accuracy and receiver-operating characteristics curve analysis in surgical research and decision making. Ann Surg 2011;253:27-34. [PMID: 21294285 DOI: 10.1097/sla.0b013e318204a892] [Cited by in Crossref: 63] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
16 Coghlin C, Murray GI. Following the protein biomarker trail to colorectal cancer. Colorectal Cancer 2012;1:93-6. [DOI: 10.2217/crc.12.7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
17 Jayasekara H, Reece JC, Buchanan DD, Ahnen DJ, Parry S, Jenkins MA, Win AK. Risk factors for metachronous colorectal cancer or polyp: A systematic review and meta-analysis. J Gastroenterol Hepatol 2017;32:301-26. [PMID: 27356122 DOI: 10.1111/jgh.13476] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
18 Toaldo C, Pizzimenti S, Cerbone A, Pettazzoni P, Menegatti E, Daniela B, Minelli R, Giglioni B, Dianzani MU, Ferretti C. PPARgamma ligands inhibit telomerase activity and hTERT expression through modulation of the Myc/Mad/Max network in colon cancer cells. J Cell Mol Med. 2010;14:1347-1357. [PMID: 19912441 DOI: 10.1111/j.1582-4934.2009.00966.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
19 Kato T, Alonso S, Muto Y, Perucho M, Rikiyama T. Tumor size is an independent risk predictor for metachronous colorectal cancer. Oncotarget. 2016;7:17896-17904. [PMID: 26910116 DOI: 10.18632/oncotarget.7555] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]